MONROVIA, Calif.--(BUSINESS WIRE)--Sep. 13, 2018-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that the FDA has granted approval of the PMA Supplement for the Visian Toric ICL for the correction of myopia with astigmatism.

This approval represents a meaningful expansion of the Implantable Collamer® Lens (ICL) product line for the correction of refractive error in patients with both myopia and astigmatism which are common conditions in the United States (US). Astigmatism affects approximately 30 percent of the population.1

The ICL in both spherical and toric designs has been associated with significant improvements in quality of life. Patients have described ICL surgery as “life changing” or wished they had opted for the surgery sooner.2 The approval of the Visian Toric ICL is also an important step towards the future availability of advanced ICL models in the US, such as the EVO/EVO+ Toric ICL.

“FDA’s approval of STAAR’s Visian Toric ICL in the U.S. provides an exciting treatment option for myopic patients with astigmatism in search of visual freedom. We are thrilled to be able to offer this lens in the United States and look forward to officially making the Visian Toric ICL available to U.S. surgeons for their patients on November 1st, 2018,” said

Caren Mason, President & CEO.

INDICATIONS:

The Directions for Use (DFU) lists the indications as: The Visian TICL is indicated for use in patients 21-45 years of age:

  1. for the correction of myopic astigmatism with spherical equivalent ranging from -3.0 D to ≤ -15.0 D (in the spectacle plane) with cylinder (spectacle plane) of 1.0 D to 4.0 D in the spectacle plane.
  2. for the reduction of myopic astigmatism with spherical equivalent ranging from greater than -15.0 D to -20.0 D (in the spectacle plane) with cylinder (spectacle plane) 1.0 D to 4.0 D in the spectacle plane.
  3. with an anterior chamber depth (ACD) of 3.00 mm or greater, when measured from the corneal endothelium to the anterior surface of the crystalline lens and a stable refractive history (within 0.5 D for both spherical equivalent and cylinder for 1 year prior to implantation).
  4. The Visian TICL is intended for placement in the posterior chamber (ciliary sulcus) of the phakic eye.

1 2017 Refractive Surgery Report: A Global Analysis from 2016 – 2022, Market Scope December 2017

2 Ieong A.et al, Quality of Life in High Myopia before and after Implantable Collamer Lens Implantation. Ophthalmology 2010;117:2295-2300

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO Visian ICL™ product line. More than 900,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.discovericl.com. STAAR has approximately 400 full-time equivalent employees and markets lenses in over 75 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company’s website at www.staar.com.

Forward-Looking Statements

This news release contains forward-looking statements. These statements include but are not limited to statements regarding the commercial significance of the Visian Toric ICL in the U.S. market. Forward-looking statements are based on our management’s current expectations or beliefs regarding future events or circumstances, and you should not place undue reliance on these statements. Such statements involve known and unknown risks, uncertainties, assumptions and other factors, many of which are out of STAAR’s control and difficult to forecast that may cause actual results to differ materially from those that may be described or implied in the forward-looking statements. STAAR cannot be certain about the commercial success of the Visian Toric ICL in the U.S. market. For a discussion of certain other risks, uncertainties and other factors affecting the statements contained in this news release, see STAAR’s Annual Report on Form 10-K for the year ended December 29, 2017, under the caption “Risk Factors,” which is on file with the SEC and available in the “Investor Information” section of STAAR’s website under the heading “SEC Filings.” Except as required by law, STAAR assumes no, and hereby disclaims any, obligation to update any of the foregoing or any other forward-looking statements. STAAR nonetheless reserves the right to make such updates from time to time by press release, periodic report or other method of public disclosure without the need for specific reference to this news release. No such update shall be deemed to indicate that other statements not addressed by such update remain correct or create an obligation to provide any other updates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005985/en/

Source: STAAR Surgical Company

ZEISS Receives FDA Approval for ReLEx SmILE, Expanding Myopia Treatment to Patients with Astigmatism

Small Incision Lenticule Extraction, better known as ReLEx SmILE from ZEISS is a minimally-invasive corneal refractive procedure performed on the ZEISS VisuMax femtosecond laser

JENA/Germany, 2018-10-05.

Today, the ZEISS Medical Technology Segment announced the FDA Premarket Approval (PMA) for ReLEx® SmILE® PMA expanding myopia treatment to patients with astigmatism. The PMA also provides for a small entry incision to be made, allowing the SmILE® procedure to be potentially less disruptive to the corneal surface tissue.

“The expansion of Myopia treatment to patients with Astigmatism will enable current and future SmILE® surgeons to expand their patient base, paving the way for a new generation of refractive surgery patients,” said Jim Mazzo, Global President Ophthalmic Devices at Carl Zeiss Meditec.

ZEISS ReLEx SmILE utilizes the high-precision femtosecond laser VisuMax® to create a lenticule inside the cornea and access incision in a single treatment step. Its outstanding cutting precision, exceptional speed and gentle treatment make it an ideal platform for advanced corneal surgery such as SmILE®. Incisions are made through microscopic-photodisruptions of tissue, created by ultrashort pulses.

Many patients are patiently awaiting this approval, reported John F. Doane, M.D., F.A.C.S. of Discover Vision Centers. “We and our patients are excited to say the least. Refractive surgery just keeps getting better with Carl Zeiss Meditec’s FDA approval of SmILE® for compound myopic astigmatism,” Doane added.

VisuMax laser is the first femtosecond laser to receive FDA PMA approval for the treatment of a refractive indication in addition to 510k clearances for LASIK flap, keratoplasty, and ICR. With the approval of ReLEx® SmILE®, patients can now benefit from a minimally invasive surgery, performed on one laser versus two.

Refractive surgeons benefit from SmILE®’s versatility, offering patients a more comfortable treatment option. With the approved new indication range the surgeon has also the option to benefit from extended technical parameters.

“Thanks to our continued collaboration with partner surgeons worldwide, we are able to pave the way for new developments and technologies in the refractive space,” said Dr. Ludwin Monz, President, and CEO of Carl Zeiss Meditec. “Now with the FDA approval for US SmILE® Astigmatism, we can now extend this great treatment option to US Astigmatism patients as well."

ReLEx® SmILE® from ZEISS made its U.S. debut in 2016. In the last 10 years, over 1.5 million SmILE® treatments have been performed worldwide constituting over 10% of global laser vision correction procedures. To date, there are over 1700 surgeons using SmILE® in over 70 countries. The technology behind SmILE was recently featured in the Scientific Background on the Nobel Prize in Physics 2018. Dr. Gérard Mourou and Dr. Donna Strickland were awarded the Nobel Prize for his method to generate high-intensity ultrashort optical pulses. Their invention of so-called chirped pulse amplification is essential to generate the ultrashort laser pulses of the ZEISS VisuMax femtosecond laser system. ReLEx® SmILE® is a registered trademark of Carl Zeiss Meditec. For more information about ReLEx® SmILE®, visit www.zeiss.com.

VisuMax® and ReLEx® SmILE® are registered trademarks of Carl Zeiss Meditec. Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.

On May 3-7, 2019, Dr. Monson addressed an international audience of refractive surgeons at the American Society of Cataract and Refractive Surgery (ARCRS) in San Diego. ASCRS mission is to advance the art and science of ophthalmic surgery and the knowledge and skills of ophthalmic surgeons by providing clinical and practice management education and by working with patients, government, and the medical community to promote the delivery and advancement of high-quality eye care. ASCRS leads the field through significant advances in technology and clinical science through its educational programs, publications and on-line resources. ASCRS has become the surgeons’ primary source of up-to-date clinical information, published research, and regulatory information affecting the practice of medicine.

Surgeons traveled from over 100 countries to learn about the latest in vision restoration surgery.

On May 3-7, 2019, Dr. Monson addressed an international audience of refractive surgeons at the American Society of Cataract and Refractive Surgery (ARCRS) in San Diego. ASCRS mission is to advance the art and science of ophthalmic surgery and the knowledge and skills of ophthalmic surgeons by providing clinical and practice management education and by working with patients, government, and the medical community to promote the delivery and advancement of high-quality eye care. ASCRS leads the field through significant advances in technology and clinical science through its educational programs, publications and on-line resources. ASCRS has become the surgeons’ primary source of up-to-date clinical information, published research, and regulatory information affecting the practice of medicine.

Surgeons traveled from over 100 countries to learn about the latest in vision restoration surgery.

© COPYRIGHT 2023 MONSON VISION
TERMS & CONDITIONSPRIVACY POLICY
menuchevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram